API | iferanserin

iferanserin Report issue

Small molecule Experimental

AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW

Iferanserin is a drug which acts as a selective 5-HT2A receptor antagonist. It is under development as an intra-rectal formulation for the treatment of hemorrhoid disease, and as of February 2012, is in phase IIb clinical trials. ^Wikipedia

Chemistry

SMILES: CN1CCCC[C@H]1CCc1ccccc1NC(=O)/C=C/c1ccccc1
InChIKey: UXIPFQUBOVWAQW-UEBLJOKOSA-N
Mol. Mass: 348.49
ALogP: 4.76 Partition coefficient
ChEMBL Molecules:

iferanserin

None

More Chemistry

Pharmacology

Mechanism of Action:
- 5-hydroxytryptamine receptor 2A (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

iferanserin | ven-309

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)

Hemorrhoids (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 2
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue